EE200100388A - Püridasino [4,5-b] indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite düsfunktsioneerimisega seotud haiguste raviks - Google Patents

Püridasino [4,5-b] indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite düsfunktsioneerimisega seotud haiguste raviks

Info

Publication number
EE200100388A
EE200100388A EEP200100388A EEP200100388A EE200100388A EE 200100388 A EE200100388 A EE 200100388A EE P200100388 A EEP200100388 A EE P200100388A EE P200100388 A EEP200100388 A EE P200100388A EE 200100388 A EE200100388 A EE 200100388A
Authority
EE
Estonia
Prior art keywords
pyridazino
indole
medicines
preparation
treatment
Prior art date
Application number
EEP200100388A
Other languages
English (en)
Inventor
Ferzaz Badia
Benavides J�sus
Marguet Frank
Froissant Jacques
Marabout Beno�t
Evanno Yannick
Sevrin Mireille
Janiak Philip
Original Assignee
Sanofi-Synthlabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthlabo filed Critical Sanofi-Synthlabo
Publication of EE200100388A publication Critical patent/EE200100388A/et
Publication of EE04905B1 publication Critical patent/EE04905B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200100388A 1999-01-26 2000-01-21 Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks EE04905B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9900806A FR2788696B1 (fr) 1999-01-26 1999-01-26 Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
PCT/FR2000/000135 WO2000044384A1 (fr) 1999-01-26 2000-01-21 UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AUX MALADIES LIEES AU DYSFONCTIONNEMENT DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES

Publications (2)

Publication Number Publication Date
EE200100388A true EE200100388A (et) 2002-12-16
EE04905B1 EE04905B1 (et) 2007-10-15

Family

ID=9541212

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100388A EE04905B1 (et) 1999-01-26 2000-01-21 Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks

Country Status (32)

Country Link
US (1) US6395729B1 (et)
EP (1) EP1148881B1 (et)
JP (1) JP4688295B2 (et)
KR (1) KR100694752B1 (et)
CN (1) CN100577167C (et)
AR (1) AR022413A1 (et)
AT (1) ATE335487T1 (et)
AU (1) AU764445B2 (et)
BG (1) BG65152B1 (et)
BR (1) BR0007718A (et)
CA (1) CA2360754C (et)
CO (1) CO5160242A1 (et)
CY (1) CY1106257T1 (et)
CZ (1) CZ294283B6 (et)
DE (1) DE60029929T2 (et)
DK (1) DK1148881T3 (et)
EE (1) EE04905B1 (et)
ES (1) ES2269097T3 (et)
FR (1) FR2788696B1 (et)
HK (1) HK1040905B (et)
HU (1) HU228670B1 (et)
IL (2) IL144181A0 (et)
NO (1) NO321997B1 (et)
NZ (1) NZ512981A (et)
PL (1) PL193420B1 (et)
PT (1) PT1148881E (et)
RU (1) RU2243764C2 (et)
SK (1) SK285707B6 (et)
TR (1) TR200102134T2 (et)
TW (1) TW541177B (et)
UA (1) UA70349C2 (et)
WO (1) WO2000044384A1 (et)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010414A2 (en) * 1998-12-02 2002-06-30 Pfizer Prod Inc METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2838124B1 (fr) * 2002-04-03 2004-05-28 Sanofi Synthelabo Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
FR2876715B1 (fr) 2004-10-19 2006-12-15 Profiles Du Ct Sa Embout de protection pour ecran de glissiere de securite routiere
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
CA2606861C (en) * 2005-05-05 2012-08-07 Sanofi-Aventis U.S. Llc Stable nanoparticle formulations
WO2007027494A2 (en) * 2005-08-29 2007-03-08 Sanofi-Aventis U.S. Llc Morphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino [4, 5-b] indole-1-acetamide
JP5063600B2 (ja) 2005-08-29 2012-10-31 サノフイ−アベンテイス・ユー・エス・エルエルシー ピリダジノ［４，５−ｂ］インドール誘導体の新規な結晶形
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及系统
FR2918563B1 (fr) 2007-07-12 2009-12-04 Oreal Composition photoprotectrice fluide aqueuse a base d'un polymere polyamide a terminaison amide tertiaire.
FR2931064B1 (fr) 2008-05-14 2010-08-13 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane
AU2009283039A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4H-pyridazin0[4,5-b]indole-1-acetamide
GB0818738D0 (en) * 2008-10-13 2008-11-19 Ge Healthcare Ltd Imaging neuroflammation
FR2936706B1 (fr) 2008-10-08 2010-12-17 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
EP2181717A1 (en) 2008-10-28 2010-05-05 Sanofi-Aventis Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels
EP2512416A2 (fr) 2009-12-18 2012-10-24 L'Oréal Procédé de traitement cosmétique impliquant un composé apte à condenser in situ
FR2960773B1 (fr) 2010-06-03 2015-12-11 Oreal Procedes de traitement cosmetique utilisant un revetement a base d'un polymere polyamide-polyether
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121137A1 (de) 1981-05-27 1982-12-16 Hoechst Ag, 6000 Frankfurt Neue pyridazino(4,5-b)indole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen, zwischenprodukte und deren herstellung"
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
US6031120A (en) * 1997-07-29 2000-02-29 E. I. Du Pont De Nemours And Company Selective synthesis of organodiphosphite compounds
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
FR2788696B1 (fr) 2004-03-05
DE60029929D1 (de) 2006-09-21
CA2360754C (en) 2008-07-08
JP2002535370A (ja) 2002-10-22
WO2000044384A1 (fr) 2000-08-03
EE04905B1 (et) 2007-10-15
PL193420B1 (pl) 2007-02-28
CN1344161A (zh) 2002-04-10
NO20013645L (no) 2001-09-26
TR200102134T2 (tr) 2003-03-21
PL349364A1 (en) 2002-07-15
NZ512981A (en) 2002-10-25
DK1148881T3 (da) 2006-12-11
BG65152B1 (bg) 2007-04-30
ATE335487T1 (de) 2006-09-15
CA2360754A1 (en) 2000-08-03
ES2269097T3 (es) 2007-04-01
NO321997B1 (no) 2006-07-31
EP1148881B1 (fr) 2006-08-09
KR20010089624A (ko) 2001-10-06
PT1148881E (pt) 2006-12-29
AU764445B2 (en) 2003-08-21
BR0007718A (pt) 2001-11-13
KR100694752B1 (ko) 2007-03-14
HK1040905A1 (en) 2002-06-28
UA70349C2 (en) 2004-10-15
CZ20012681A3 (cs) 2001-10-17
AU3057900A (en) 2000-08-18
AR022413A1 (es) 2002-09-04
CO5160242A1 (es) 2002-05-30
NO20013645D0 (no) 2001-07-24
SK285707B6 (sk) 2007-06-07
FR2788696A1 (fr) 2000-07-28
RU2243764C2 (ru) 2005-01-10
BG105728A (en) 2002-02-28
CY1106257T1 (el) 2011-06-08
HUP0201280A2 (en) 2002-08-28
TW541177B (en) 2003-07-11
HK1040905B (zh) 2007-02-23
SK10502001A3 (sk) 2002-01-07
JP4688295B2 (ja) 2011-05-25
IL144181A (en) 2007-06-17
CZ294283B6 (cs) 2004-11-10
DE60029929T2 (de) 2007-08-30
CN100577167C (zh) 2010-01-06
US6395729B1 (en) 2002-05-28
EP1148881A1 (fr) 2001-10-31
HU228670B1 (en) 2013-05-28
IL144181A0 (en) 2002-05-23
HUP0201280A3 (en) 2004-12-28

Similar Documents

Publication Publication Date Title
EE04905B1 (et) Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks
EE04313B1 (et) 1,2,4-triasolo[4,3-b]pürido[3,2-d]püridasiini derivaadid, nende valmistamismeetod ja farmatseutiline kompositsioon ning nende kasutamine
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
EE200200046A (et) 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
HUP0203545A3 (en) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives, pharmaceutical compositions containing them, process for their preparation and their use
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
EE200100377A (et) Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
EE03830B1 (et) 1H-pürido[3,4-b]indool-4-karboksamiidi derivaadid, nende valmistamismeetodid ja kasutamine raviks
HUP0105054A3 (en) Imidazo[4,5-c]-pyridine-4-on-derivatives, pharmaceutical compositions containing them and process for their preparation
SI1176976T2 (sl) Uporaba LH, dajanega v srednji ali pozni folikularni fazi, za zdravljenje anovulatornih žensk
NZ515882A (en) Treatment of serotonin related disorders with 2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives
DK1000063T3 (da) 4-oxo-3,5-dihydro-4H-pyridazin[4,5-b]indol-1-acetamidderivater, fremstilling heraf og terapeutisk anvendelse heraf
DE60002043D1 (de) 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]indol-1-carboxamid-derivate, ihre herstellung und therapeutische verwendung
HUP0300569A3 (en) Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders and pharmaceutical compositions containing the compounds
HUP0204391A3 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
LV12188A (lv) 1,4-Dihidro-1,4-diokso-1H-naftalina triciklisku atvasinajumu pielietojums jaunu savienojumu iegusanai un to izmantosana terapija
NO20001894D0 (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
AU2001278549A1 (en) Use of pyridazino(4,5-)indole-1-acetamide derivatives for preparing medicines for treating pathologies related to the dysfunction of peripheral benzodiazepin receptors
EP0791594A3 (en) 2-Aryl-5,11-dihydro-6H-dipyrido 3,2-b:2',3'-e 1,4 diazepines and their use for the preparation of pharmaceutical compositions for the treatment of HIV infection
PL371201A1 (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
EE200100700A (et) Asendatud [1,4]diasepino[6,7,1-hi]indool-4-oonidevalmistamismeetod
MXPA05008490A (es) Combinaciones que contienen imidazopiridinas y su uso en el tratamiento de enfermedades gastrointestinales inflamatorias.
AU2001282410A1 (en) N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20140121